Badger A M, Buehler R J, Cooperband S R
Cancer Res. 1978 Oct;38(10):3365-70.
Ascitic fluids from patients with cancer, cirrhosis, and congestive heart failure and from a patient with noninfectious tuberculosis contain measurable levels of tissue polypeptide antigen (TPA). Only the cancer patients had levels higher than 2.0 microgram TPA per ml. The average TPA levels of 29 cancer patients was 6.4 microgram/ml compared to 0.9 microgram/ml for the controls. Seventeen of 22 cancer ascitic fluids and 7 of 9 fluids from patients with liver disease were immunosuppressive as measured by the inhibition of [3H]thymidine incorporation into phytohemagglutinin-stimulated lymphocytes. Fluids from a patient with congestive heart failure and a patient with noninfectious tuberculosis were not suppressive. We were unable to obtain a significant correlation coefficient between immunosuppression and TPA levels in these fluids. In addition, TPA levels remained constant over a period of 18 months of testing, whereas the in vitro immunosuppressive activity was lost in 9 to 10 months. Sephadex G-200 fractionation of the ascitic fluid resulted in the TPA and immunosuppressive activity eluting in the first large molecular weight peak from the column. Although the 2 activities eluted together in this fractionation, the data suggest that TPA is not responsible for the immunosuppression.
来自癌症、肝硬化、充血性心力衰竭患者以及一名非感染性肺结核患者的腹水含有可测量水平的组织多肽抗原（TPA）。只有癌症患者的TPA水平高于每毫升2.0微克。29名癌症患者的TPA平均水平为6.4微克/毫升，而对照组为0.9微克/毫升。通过[3H]胸腺嘧啶核苷掺入植物血凝素刺激的淋巴细胞的抑制作用来测量，22份癌症腹水样本中的17份以及9份肝病患者的腹水样本中的7份具有免疫抑制作用。充血性心力衰竭患者和非感染性肺结核患者的腹水没有抑制作用。我们未能在这些腹水中的免疫抑制作用与TPA水平之间获得显著的相关系数。此外，在18个月的检测期间，TPA水平保持恒定，而体外免疫抑制活性在9至10个月内丧失。腹水经葡聚糖凝胶G - 200分级分离后，TPA和免疫抑制活性在柱上的第一个大分子量峰中洗脱。尽管在这种分级分离中这两种活性一起洗脱，但数据表明TPA与免疫抑制作用无关。
